Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.
2.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
3.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
4.

Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma.

Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU.

Am J Obstet Gynecol. 2013 Aug;209(2):142.e1-6. doi: 10.1016/j.ajog.2013.04.014. Epub 2013 Apr 10.

PMID:
23583212
5.

CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.

Presl J, Novotny Z, Topolcan O, Vlasak P, Kucera R, Fuchsova R, Vrzalova J, Betincova L, Svobodova S.

Anticancer Res. 2014 Jan;34(1):327-31.

PMID:
24403483
6.

Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.

Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R.

Clin Chem. 2011 Nov;57(11):1534-44. doi: 10.1373/clinchem.2010.157073. Epub 2011 Sep 20.

7.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
8.

The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.

Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A, Luvero D, Cafà EV, Dugo N, Angelucci M, Benedetti-Panici P.

Tumour Biol. 2013 Feb;34(1):571-6. doi: 10.1007/s13277-012-0583-0. Epub 2012 Nov 20.

PMID:
23179397
9.

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.

Zheng H, Gao Y.

Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.

PMID:
22426406
10.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
11.

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Azzam AZ, Hashad DI, Kamel NA.

Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.

PMID:
23361457
12.

Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.

Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, Sun L, Duan C, Luo X, Yan H.

Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.

PMID:
25447698
13.

TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.

Peters-Engl C, Buxbaum P, Ogris E, Sevelda P, Medl M.

Anticancer Res. 1998 Nov-Dec;18(6B):4635-9.

PMID:
9891532
14.

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K.

Gynecol Oncol. 2008 Aug;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002. Epub 2008 May 21.

15.

HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).

Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, Fagö-Olsen CL, Andersen ES, Jochumsen K, Høgdall C.

Acta Obstet Gynecol Scand. 2013 Nov;92(11):1313-22. doi: 10.1111/aogs.12235.

PMID:
24032654
16.

Serum HE4 as a prognostic marker in endometrial cancer--a population based study.

Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y, Freemantle M; ANECS Group, Webb PM, Spurdle AB, Obermair A.

Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.

PMID:
24211402
17.

HE4 is an independent prognostic marker in endometrial cancer patients.

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A.

Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.

PMID:
22525819
18.

LyGDI is a promising biomarker for ovarian cancer.

Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L, Zhang X.

Int J Gynecol Cancer. 2010 Apr;20(3):316-22. doi: 10.1111/IGC.0b013e3181d0b02d.

PMID:
20375790
19.

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A.

Br J Cancer. 2011 Apr 26;104(9):1418-25. doi: 10.1038/bjc.2011.109. Epub 2011 Apr 5.

20.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.

Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2011 Aug;21(6):1040-7. doi: 10.1097/IGC.0b013e31821e052e.

PMID:
21738039

Supplemental Content

Support Center